Introduction {#S0001}
============

Thyroid cancer (TC) is the most common endocrine malignancy, with an estimated 53,990 new cases in the US in 2018.[@CIT0001] The incidence rate for TC has increased more than 2.5 folds (5.57/100,000--13.98/100,000) in the recent decades.[@CIT0002] This progressive increase was nearly entirely attributable to an increase in papillary thyroid carcinoma (PTC). Differentiated thyroid carcinoma is the major subtype of TC, and is subdivided into papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC). PTC is the most common type of differentiated TC, accounting for approximately 90% of all the cases.[@CIT0003] Radical surgical intervention remains the primary treatment for TC. Despite a favorable rate of survival for PTC, the risk of recurrence ranges from 5% to 21%.[@CIT0004],[@CIT0005]

The TNM Cancer Staging System of the American Joint Committee on Cancer (AJCC) is the most widely used system to predict the survival outcomes.[@CIT0006] In this classification system, patients are stratified according to depth of invasion (T), number of metastatic nodes (N), and the status of distant metastasis (M). This system is effective for patient populations but is not very useful in predicting individual patient outcomes.[@CIT0007] In addition, it does not account for other variables, such as sex, race, marital status, multifocality, surgery, presence of vascular invasion, margin status, and radioactive iodine, which have been identified as independent prognostic factors in TC.[@CIT0008]--[@CIT0010]

Nomograms have been accepted as reliable tools to accurately predict an individual's clinical outcome by utilizing multiple variables. Nomograms provide a visual explanation for the predicted probabilities of an outcome as obtained by statistical predictive models. They were created by regression analysis and have extended beyond the standard TNM anatomical criteria.[@CIT0011] Nomograms have been widely used in multiple malignancies due to their ability to handle the complexity in a systematic and unbiased manner.[@CIT0012]--[@CIT0015] Well-designed nomograms have been incorporated into the National Comprehensive Cancer Network (NCCN) guidelines.[@CIT0016],[@CIT0017] Nevertheless, no nomograms are available for individual PTC patients on the basis of population-based data. Therefore, we aimed to develop a prognostic nomogram based on the large population of PTC data retrieved from the Surveillance, Epidemiology and End Results (SEER) database, to predict the individualized survival in patients with PTC.

Patients and methods {#S0002}
====================

Patients {#S0002-S2001}
--------

This study is a retrospective cohort analysis using data from the SEER database which was designed and maintained by the National Cancer Institute (NCI). The SEER database collects clinical information on various cancer types for associated incidence, prevalence, and survival from 17 population-based cancer registries covering approximately 28% of the US population.[@CIT0018] We used the SEER\*STAT software (version 8.3.5) to extract data from the SEER database. The cohort for this analysis consisted of adult patients (≥18 years) diagnosed with PTC who underwent thyroid surgery between 2004 and 2013. The histological subtypes of PTC were limited using the site code C73.9 and the International Classification of Diseases for Oncology-3: 8050, 8260, 8340--8344. The exclusion criteria were: (1) patients with second primary malignancies, (2) patients diagnosed at autopsy and those lost to follow-up, and (3) patients with incomplete clinical information (marital status, cause of death, survival month, tumor size, staging information, and follow-up months). All patients were randomly assigned to either the training set for nomograms or the validation set for the purposes of validation. Neither ethical approval nor informed consent was required because the data is publicly available, and the database does not hold any identifying patient data.

Variables {#S0002-S2002}
---------

Several variables, including age, sex, race, marital status, tumor size, extrathyroidal extension, multifocality, surgery, radioactive iodine, T stage, N stage, and M stage were collected in the training set. Tumor size was categorized as "≤1.0 cm", "1.1--2.0 cm", "2.1--4.0 cm", and "\>4 cm". The primary end point was the overall survival (OS) and cancer specific survival (CSS). While the OS was defined as the time from diagnosis of PTC to death or censoring, the CSS was defined as the time from diagnosis to death due to PTC or censoring.

Statistical analyses {#S0002-S2003}
--------------------

The baseline patient features were compared using the Chi-square test. Survival curves were depicted using the Kaplan-Meier method and compared using the log-rank test. The construction of nomograms was based on the independent prognostic variables determined by multivariate Cox proportional hazards regression analyses. Variables were selected through the backward stepwise selection method with a threshold of *P*\<0.050. The performance of the nomogram was evaluated by discrimination and calibration. Discrimination was assessed using the concordance index (C-index), which is similar to the area under receiver operating characteristic (ROC) curve (AUC), with values ranging from 0.5 (no discrimination) to 1.0 (perfect discrimination)[@CIT0019] Calibration was performed by comparing the observed versus predicted mean survival rate. Significance was achieved at *P*\<0.05 in a two-tailed test. Statistical analyses were conducted using the SPSS version 23 (IBM, Armonk, NY, USA), and the nomogram was constructed using R version 3.5.1 (<http://www.r-project.org>) via the design and survival packages.

Results {#S0003}
=======

Clinicopathological features {#S0003-S2001}
----------------------------

In total, 63,219 eligible PTC patients were selected and randomly assigned into a training set (n=31,610) and a validation set (n=31,609). The flow diagram of data selection is presented in [Figure 1](#F0001){ref-type="fig"}. In the whole study cohort, 35,337 (55.9%) patients were older than 45 years. While 49,959 (79.0%) patients were women, 13,260 (21.0%) of them were men. Most tumors (55.6%) were ≤1.0 cm in size. Multifocal tumors were observed in 26,546 (42.0%) patients and a gross extrathyroidal extension of cancer in 10,047 (15.9%) patients. Total thyroidectomy was performed in 83.4% of all the patients, and 49.0% of them received adjuvant radioactive radioiodine. Most patients (62.5%) were categorized as having T1 stage cancer. Additionally, a few patients had lymph node invasion (22.6%) and distant metastasis (99.2%) at diagnosis.Figure 1Flow chart of the data selection process.**Abbreviation:** PTC, papillary thyroid cancer.

The median follow-up was 68 months (1--143 months). By the end of the follow up, 2015 of the 63,219 (3.2%) patients had died, which included 545 deaths due to PTC and 1,470 due to other causes. The clinicopathologic characteristics of the patients are listed in [Table 1](#T0001){ref-type="table"}.Table 1Patient demographics and pathological characteristicsVariablesAll patients (n=63,219)Training set (n=31,610)Validation set (n=31,609)*P*-valueNo.%No.%No.%Age0.193 \<4527,88244.113,86043.814,02244.4 ≥4535,33755.917,75056.217,58755.6Sex0.583 Female49,95979.025,00879.124,95178.9 Male13,26021.06,60220.96,65821.1Race0.952 White52,19582.626,08382.526,11282.6 Black3,8256.11,9176.11,9086.0 Other7,19911.43,61011.43,58911.4Marital status0.100 Married42,46967.221,33267.521,13766.9 Unmarried20,75032.810,27832.510,47233.1Tumor Size0.658 ≤1.0 cm25,98441.113,01241.212,97241.0 1.1--2.0 cm18,77829.79,43729.99,34129.6 2.1--4.0 cm13,78621.86,83521.66,95122.0 \>4.0 cm4,6717.42,3267.42,3457.4Extrathyroidal extension0.101 Absent53,17284.126,51183.926,66184.3 Present10,04715.95,09916.14,94815.7Multifocality0.131 Unifocal36,67358.018,24357.718,43058.3 Multifocal26,54642.013,36742.313,17941.7Surgery0.369 Lobectomy10,52216.65,21916.55,30316.8 Total thyroidectomy52,69783.426,39183.526,30683.2Radioactive iodine0.997 Yes30,95049.015,47549.015,47549.0 No32,26951.016,13551.016,13451.0T stage0.352 T139,52062.519,77162.519,74962.5 T210,25716.25,06316.05,19416.4 T311,34617.95,70218.05,64417.9 T42,0963.31,0743.41,0223.2N stage0.134 N048,92777.424,38577.124,54277.6 N114,29222.67,22522.97,06722.4M stage0.320 M062,72799.231,35399.231,37499.3 M14920.82570.82350.7

Construction and validation of nomograms {#S0003-S2002}
----------------------------------------

Data on age at diagnosis, sex, race, marital status, tumor size, extrathyroidal extension, multifocality, surgery, radioactive iodine, T stage, N stage, and M stage were collected and analyzed for patients in both the training and validation sets. Univariate analysis showed that 10 of the above variables were significantly associated with OS in the training set (*P*\<0.05). After performing a multivariate analysis, 9 out of the 10 variables (age, sex, race, marital status, tumor size, extrathyroidal extension, radioactive iodine, T stage, and M stage) were found to be significantly associated with OS ([Table 2](#T0002){ref-type="table"}). Therefore, a nomogram of the OS was established with these independent variables in the training set ([Figure 2A](#F0002){ref-type="fig"}). As is shown in [Table 3](#T0003){ref-type="table"}, 8 variables (age, sex, marital status, tumor size, extrathyroidal extension, T stage, N stage, and M stage) were confirmed to have a significant impact on patient CSS by both univariate and multivariate analyses in the training set (*P*\<0.05). A nomogram for predicting the 10-year CSS was constructed based on the independent variables ([Figure 2B](#F0002){ref-type="fig"}).Table 2Univariate and multivariate analyses of overall survival in the training setVariableUnivariate AnalysisMultivariate analysis*P-*ValueHR (95%CI)*P-*ValueAge\<0.001 \<45Reference ≥452.706 (2.339--3.131)\<0.001Sex\<0.001 FemaleReference Male1.919 (1.681--2.192)\<0.001Race0.005 WhiteReference Black1.471 (1.185--1.825)0.014 Other0.849 (0.687--1.048)0.127Marital status\<0.001 MarriedReference Unmarried1.939 (1.709--2.199)\<0.001Tumor Size\<0.001 ≤1.0 cmReference 1.1--2.0 cm0.954 (0.799--1.139)0.603 2.1--4.0 cm1.445 (1.080--1.934)0.013 \>4.0 cm2.787 (2.087--3.721)\<0.001Extrathyroidal extension\<0.001 AbsentReference Present2.297 (1.665--3.170)\<0.001Multifocality0.685 Unifocal MultifocalSurgery0.521 Lobectomy Total thyroidectomyRadioactive iodine\<0.001 YesReference No1.901 (1.669--2.167)\<0.001T stage\<0.001 T1Reference T20.706 (0.504--0.988)0.042 T30.563 (0.390--0.814)0.002 T41.418 (0.910--2.207)0.123N stage\<0.001 N0Reference N11.104 (0.945--1.289)0.214M stage\<0.001 M0Reference M16.374 (5.054--8.038)\<0.001 Table 3Univariate and multivariate analyses of cancer-specific survival in the training setVariableUnivariate analysisMultivariate analysis*P-*valueHR (95%CI)*P-*valueAge\<0.001 \<45Reference ≥453.702 (2.667--5.139)\<0.001Sex\<0.001 FemaleReference Male1.542 (1.2058--1.972)\<0.001Race0.018 WhiteReference Black1.291 (0.790--2.109)0.309 Other1.213 (0.881--1.668)0.236Marital status0.008 MarriedReference Unmarried1.423 (1.116--1.816)0.004Tumor Size\<0.001 ≤1.0 cmReference 1.1--2.0 cm1.272 (0.773--2.094)0.343 2.1--4.0 cm2.240 (1.295--3.874)0.004 \>4.0 cm4.351 (2.521--7.507)\<0.001Extrathyroidal extension\<0.001 AbsentReference Present2.017 (1.209--3.365)0.007Multifocality0.506 Unifocal MultifocalSurgery0.191 Lobectomy Total thyroidectomyRadioactive iodine0.925 Yes NoT stage\<0.001 T1Reference T21.143 (0.582--2.246)0.698 T31.808 (0.935--3.497)0.079 T47.009 (3.312--14.834)\<0.001N stage\<0.001 N0Reference N11.643 (1.253--2.153)\<0.001M stage\<0.001 M0Reference M18.462 (6.334--11.307)\<0.001 Figure 2Nomogram for predicting 10-year OS (**A**) and CSS (**B**) of patients with PTC.

We next validated the nomograms. Following an internal validation in the training set, the C-indices for the nomograms to predict the OS and CSS were 0.776 (95% CI: 0.770--0.792) and 0.924 (95%CI: 0.907--0.941), respectively. Following an external validation using the validation set, C-indices were found to be 0.770 (95% CI: 0.753--0.787) and 0.925 (95% CI: 0.905--0.945) for the OS and CSS nomograms, respectively. The calibration curve showed good agreement between prediction and observation in the probability of 10-year OS and CSS in both the training and validation sets ([Figure 3](#F0003){ref-type="fig"}). Furthermore, comparisons were performed between the nomograms and TNM 6th staging system in the training set. Results comparable to those of the TNM staging system were obtained with nomograms for the OS (C-index=0.776, 95% CI: 0.770--0.792 vs 0.317, 95% CI: 0.301--0.333) and CSS (C-index=0.924, 95% CI: 0.907--0.941 vs 0.152, 95% CI: 0.136--0.168). Moreover, discrimination was also enhanced with the nomogram compared to the TNM staging system when analyzed in the validation set ([Table 4](#T0004){ref-type="table"}).Table 4C-indexes for the nomograms and other stage systems in patients with PTCSurvivalTraining setValidation setHR95%CIHR95%CIOSNomogram0.7760.770--0.7920.7700.7530.787TNM 6th stage0.3170.301--0.3330.3300.313--0.347CSSNomogram0.9240.907--0.9410.9250.905--0.945TNM 6th stage0.1520.136--0.1680.1520.135--0.169[^1] Figure 3Calibration plots of the training and validation sets for the OS and CSS associated nomograms.**Notes:** (**A, B**) The calibration plots of the training set in 10-year OS and CSS; (**C, D**) the calibration plots of the validation set in 10-year OS and CSS. The x-axis represents the nomogram-predicted survival rate, whereas the y-axis represents the actual survival rate.**Abbreviations:** OS, overall survival; CSS, cancer-specific survival.

Comparison of AUC values of the nomogram and TNM 6th staging system {#S0003-S2003}
-------------------------------------------------------------------

The predictive abilities of the nomograms and the TNM 6th staging system were compared by analyzing the AUC values ([Figure 4](#F0004){ref-type="fig"}). The AUC values for the nomogram and the TNM 6th staging system predicting the 10-year OS rates were 0.734 and 0.524, respectively, while those for predicting the 10-year CSS rates were 0.894 and 0.569, respectively. Taken together, the OS and CSS nomograms showed superior discriminative capacity compared to the TNM 6th staging system.Figure 4Comparison of the AUCs of the nomogram and TNM staging system in training set.**Notes:** Area under the curves of the two models to predict 10-years OS (**A**) and CSS (**B**) in the training set. The blue lines represent nomogram-predicted overall survival rates, whereas the red lines represent TNM stage-predicted overall survival rates.**Abbreviations:** AUC, area under ROC curve; CSS, cancer-specific survival; OS, overall survival; ROC, receiver operating characteristic.

Discussion {#S0004}
==========

Several scoring systems are used for prognostic purposes. Although these systems are easier to use in the clinic, they provide a stratified population risk assessment rather than an individualized patient risk.[@CIT0006],[@CIT0020]--[@CIT0022] Nomograms are useful tools, which have been widely used for predicting survival outcomes in individual patients. They address the complexity of balancing different variables through statistical modelling and risk quantification. Their systematic approach also avoids the bias of individual physicians or individual abnormal clinical variables. Nomograms have been proven to be superior to the traditional staging scoring systems in a variety of tumors.[@CIT0015],[@CIT0023],[@CIT0024] In addition, they may be the most valuable when the potential benefits of added therapy are unclear.[@CIT0025],[@CIT0026] They are also very useful for individualized risk stratification and help doctors in the management of clinical care when no firm guidelines are available.

To the best of our knowledge, this is the first study that describes the development and validation of nomograms to predict 10-year OS and CSS in patients with PTC. A total of 63,219 patients from the SEER dataset were analyzed in this study. Our nomograms displayed favorable discrimination and calibration. Furthermore, the ROC curve showed that the nomograms had better predictive ability than the 6th AJCC staging system. Our nomogram models are easy-to-use clinical tools which can help with patient counselling and personalized treatment.

Our nomograms identified several independent factors that could influence the prognosis in PTC patients. The results showed that most patients older than 45 years of age had the worst OS and CSS. Studies have shown that age is a major determinant of thyroid CSS.[@CIT0027] Older age has been identified as an independent risk factor, suggesting that older patients have lower survival rates.[@CIT0028]--[@CIT0030] Multiple studies have found that patients with TC who are older than 45 years of age usually have a poor prognosis.[@CIT0008],[@CIT0031] With advancing age, there is a higher risk of a histological phenotype.[@CIT0032] The previous edition of the AJCC staging system used 45-years as the cut-off value for age, while the recent eight edition uses 55 years. However, regardless of the cut-off value, age is identified as an important prognostic factor.

The difference in the incidence of TC in the two sexes has also been well documented.[@CIT0033] The incidence of TC is higher in women compared to men, though the clinical outcomes are worse in men.[@CIT0034] Our results were consistent with those of previous studies. In addition to the above factors, marital status, tumor size, extrathyroidal extension, T stage, N stage, and M stage were also identified as significant predictors of prognosis. However, we found that multifocality, surgery, and radioactive iodine were not risk factors of the 10-year CSS.

Our study has several limitations. First, the nomograms were constructed from retrospective data. Therefore, the potential risk of selection bias cannot be ruled out. Second, due to the rare specific mortality in PTC, the evaluation of the risk of recurrence may be more meaningful than death. However, the SEER database did not have data on recurrence, and therefore it could not be evaluated. Third, in spite of the patients being chosen randomly, there was still a significant difference between the numbers of male and female patients, which could have resulted in gender bias. Finally, some other critical prognostic factors, such as margin status, calcitonin, extent of surgery, radioiodine dosage, thyrotropin suppression, *BRAF* point mutation, and *TERT* promotor point mutation, were unavailable in the SEER database.

In conclusion, we were successful in establishing and validating nomograms to predict the 10-year OS and CSS in individual patients with PTC based on a large study cohort. Our nomograms could be convenient, individualized predictive tools for prognosis, which can help surgeons perform personalized survival evaluation and mortality risk identification in PTC patients.
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